Full Press Release Details
BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing.
BBIO
BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing
Key Takeaway: BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing